Nonselective ETA/ETB-receptor blockade increases systemic blood pressure of Bio 14.6 cardiomyopathic hamsters

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 6, 2008, Pages 394-401

  Honoré, Jean Claude ^a   Carrier, Émilie ^a   Fecteau, Marie Hélène ^a   Tirapelli, Carlos R ^a   Bkaily, Ghassan ^a   D'Orleans Juste, Pedro ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Atrasentan; Cardiac parameters; Cardiomyopathic hamster; Endothelin receptors; Endothelin 1

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ATRASENTAN; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; NITRATE; NITRITE; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOMYOPATHY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING; SYRIAN HAMSTER; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; HAMSTER; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; CARDIOMYOPATHIES; CRICETINAE; ENDOTHELIN-1; HEART FAILURE; HEMODYNAMICS; MESOCRICETUS; NITRATES; NITRITES; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; VENTRICULAR FUNCTION, LEFT;

EID: 44949169575     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-041     Document Type: Conference Paper

References (25)

1. Berthiaume, N., Yanagisawa, M., Labonte, J., and D'Orleans-Juste, P. 2000. Heterozygous knock-Out of ET(B) receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension, 36: 1002-1007. PMID:11116115.
2. Chang, K.W., Laconi, S., Mangold, K.A., Hubchak, S., and Scarpelli, D.G. 1995. Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas. Cancer Res. 55: 2560-2568. PMID:7780969.
3. Chiou, W.J., Wessale, J.L., Von Geldern, T., Opgenorth, T.J., and Wu-Wong, J.R. 2000. 'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects. J. Cardiovasc. Pharmacol. 36: S48-S52. PMID:11078333.
4. D'Orleans-Juste, P., Yano, M., Maurice, M.C., and Gratton, J.P. 1995. Hyperresponsiveness to ET-1 after treatment with a mixture of ETA and ETB receptor antagonists in the rabbit in vivo and in vitro. J. Cardiovasc. Pharmacol. 26 (Suppl 3): S369-S372. PMID:8587417.
5. D'Orleans-Juste, P., Labonte, J., Bkaily, G., Choufani, S., Plante, M., and Honoré, J.C. 2002. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol. Ther. 95: 221-238. doi:10.1016/S0163-7258(02)00235-8. PMID:12243796.
6. Dupuis, J., Goresky, C.A., and Fournier, A. 1996. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J. Appl. Physiol. 81: 1510-1515. PMID:8904561.
7. Gertz, E.W. 1972. Cardiomyopathic Syrian hamster: a possible model of human disease. Prog. Exp. Tumor Res. 16: 242-260. PMID:4261129.
8. Gratton, J.P., Rae, G.A., Bkaily, C., and D'Orleans-Juste, P. 2000. ET(B) receptor blockade potentiates the pressor response to big endothelin-1 but not big endothelin-2 in the anesthetized rabbit. Hypertension, 35: 726-731. PMID:10720586.
9. Honoré, J.C., Fecteau, M.H., Wessale, J.L., and D'Orleans-Juste, P. 2004. Effects of Selective and Non-Selective Endothelin Receptor Blockade on ET-1-Induced Pressor Response in the Hamster. J. Cardiovasc. Pharmacol. 44: S68-S71. PMID:15838362.
10. Honoré, J.C., Fecteau, M.H., Brochu, I., Labonte, J., Bkaily, G., and D'Orleans-Juste, P. 2005. Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster. Am. J. Physiol. Heart Circ. Physiol. 289: H1258-H1264. doi:10.1152/ajpheart.00352.2005. PMID:15879484.
11. Hoshino, T., Yamauchi, R., Kikkawa, K., Yabana, H., and Murata, S. 1998. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 286: 643-649. PMID:9694915.
12. Matsumoto, Y., Aihara, H., Yamauchi-Kohno, R., Reien, Y., Ogura, T., Yabana, H., et al. 2002. Long-term endothelin a receptor blockade inhibits electrical remodeling in cardiomyopathic hamsters. Circulation, 106: 613-619. PMID:12147545.
13. McMurray, J., and Pfeffer, M.A. 2002. New therapeutic options in congestive heart failure: Part I. Circulation. 105: 2099-2106. doi:10.1161/01.CIR.0000014763.63528.9D. PMID:11980691.
14. Miyauchi, T., Kobayashi, T., Yamauchi, R., Hoshino, T., Sakai, S., Kikkawa, K., et al. 1998. Cloning of hamster preproendothelin-1 cDNA and its expression in the heart. J. Cardiovasc. Pharmacol. 31 (Suppl 1): S298-S301. doi:10.1097/00005344-199800001-00083. PMID:9595464.
15. Moe, G.W., Rouleau, J.L., Nguyen, Q.T., Cernacek, P., and Stewart, D.J. 2003. Role of endothelins in congestive heart failure. Can. J. Physiol. Pharmacol. 81: 588-597. doi:10.1139/y03-011. PMID:12839270.
16. Mulder, P., Richard, V., Derumeaux, G., Hogie, M., Henry, J.P., Lallemand, F., et al. 1997. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation, 96: 1976-1982. PMID:9323089.
17. Mulder, P., Boujedaini, H., Richard, V., Derumeaux, G., Henry, J.P., Renet, S., et al. 2000. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation, 102: 491-493. PMID:10920058.
18. Opgenorth, T.J., Adler, A.L., Calzadilla, S.V., Chiou, W.J., Dayton, B.D., Dixon, D.B., et al. 1996. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276: 473-481. PMID:8632312.
19. Pollock, D.M. 2001. Contrasting pharmacological ETB receptor blockade with genetic ETB deficiency in renal responses to big ET-1. Physiol. Genomics, 6: 39-43. PMID:11395545.
20. Remuzzi, G., Perico, N., and Benigni, A. 2002. New therapeutics that antagonize endothelin: promises and frustrations. Nat. Rev. Drug Discov. 1: 986-1001. doi:10.1038/nrd962. PMID:12461520.
21. Sakai, S., Miyauchi, T., Kobayashi, M., Yamaguchi, I., Goto, K., and Sugishita, Y. 1996. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature, 384: 353-355. doi:10.1038/384353a0. PMID:8934519.
22. Strachan, F.E., Spratt, J.C., Wilkinson, I.B., Johnston, N.R., Gray, G.A., and Webb, D.J. 1999. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension, 33: 581-585. PMID:9931169.
23. Von Geldern, T.W., Tasker, A.S., Sorensen, B.K., Winn, M., Szczepankiewicz, B.G., Dixon, D.B., et al. 1999. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity. J. Med. Chem. 42: 3668-3678. doi:10.1021/jm990170q. PMID:10479298.
24. Wessale, J.L., Adler, A.L., Novosad, E.I., Calzadilla, S.V., Dayton, B.D., Marsh, K.C., et al. 2002. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies. Clin. Sci. (Lond.), 103 (Suppl 48): 112S-117S. PMID:12193067.
25. Yamauchi-Kohno, R., Miyauchi, T., Hoshino, T., Kobayashi, T., Aihara, H., Sakai, S., et al. 1999. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation, 99: 2171-2176. PMID:10217659.